Oligonucleotide (siRNA) · Gene silencing: EGFR · developed by Benitec Biopharma
BB-401 is a plasmid DNA expression vector encoding a short hairpin RNA against EGFR. After intratumoral administration it is taken up by tumor cells, where the shRNA is processed into siRNA that binds EGFR RNA and blocks EGFR protein expression. It is studied in head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03433027 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Completed | BNTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Head and Neck Squamous Cell Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTC page.
See BNTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTC catalysts and pipeline →